Personalized AI designed cancer therapies are no longer science fiction. Evaxion Biotech are pioneering the development and at this event they will tell us about their AI platforms and how they are working on being ready for the next big virus.
Personalized AI designed cancer therapies are no longer science fiction. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune response. Hence, identification and design of neoepitopes enables development of cancer immuno-therapies.
At this event, Rasmus and Michael will present PIONEER an AI platform for rapid discovery and design of patient-specific neoepitopes. Within 24 hours it identifies and designs patient-specific neoepitopes which can be used in drug product manufacturing. Clinical studies are currently underway and show promising results.
RAVEN is another Evaxion platform that will be presented. It is a protype rapid-response platform for quickly designing vaccine targets from emerging epi- or pandemic viruses. Based on PIONEER, RAVEN is a 100 % in silico platform capable of identifying viral targets capable of giving rise to an immunogenic response providing protection from infection. Unlike PIONEER however, RAVEN had to be designed to deal with the complex interaction between variability in both human immune systems and mutating virus variants.
As the SARS-CoV-2 pandemic progresses and the scientific community is producing data at a rate never seen before, RAVEN is being continuously developed to be ready for the next emerging virus.
Join IDA Bioscience for an afternoon of learning more about the development of these novel immunotherapies for cancer and infectious diseases – will we be ready for the next emerging virus?
17.00: Introduction by IDA Bioscience
17.10: Presentation by Rasmus Villebro, Evaxion Biotech
17.40: Networking over sandwiches
18.10: Presentation by Michael Schantz Klausen, Evaxion Biotech
18.40: Wrap up
About Evaxion Biotech A/S
Evaxion Biotech is an AI-immunology platform company using their proprietary artificial intelligence technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop unique immunotherapies for patients.
About Rasmus Villebro
Rasmus has a master's degree in bioinformatics from the Technical University of Denmark (DTU). As part of his DTU degree he has been on exchange to McGill University, Montreal, Canada and University of Queensland, Brisbane, Australia. He has been working at Evaxion Biotech since he finished his studies in 2018. His primary function is to help develop the PIONEER platform and run PIONEER on patient data for the ongoing clinical studies.
About Michael Schantz Klausen
Michael has a PhD in bacterial synthetic biology and high-throughput data generation from the Technical University of Denmark. Michael has been with Evaxion since 2019, working on developing the PIONEER and RAVEN platforms.
Not a member? In order to sign up, you must create a user profile
. Note, when creating a user profile, you will be able to access IDA's online services - you will not become a member of IDA.
Important information regarding personal data on participant lists
Your name, title and company will appear on the attendance list for this event. The participant list is available to the organizer and the other participants on the event itself, in the form of an online attendance list. If you cancel your registration to the event, your information will not appear on the attendance list.